| Current Price | $224.76 | Mkt Cap | $20.6B |
|---|---|---|---|
| Open | $228.40 | P/E Ratio | 0.00 |
| Prev. Close | $226.80 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $223.61 - $230.26 | Volume | 502,114 |
| 52-Wk Range | $107.44 - $232.00 | Avg. Daily Vol. | 1,013,342 |
A medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for people with diabetes.
| Current Price | $224.76 | Mkt Cap | $20.6B |
|---|---|---|---|
| Open | $228.40 | P/E Ratio | 0.00 |
| Prev. Close | $226.80 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $223.61 - $230.26 | Volume | 502,114 |
| 52-Wk Range | $107.44 - $232.00 | Avg. Daily Vol. | 1,013,342 |
The best Bull and Bear pitches based on recency and number of recommendations.
Its platform agnostic blood glucose monitor is a component in both Insulet and Tandem Diabetes closed-loop (artificial pancreas) solution and efforts to pair up DexCom's CGMs with other insulin systems, including smart pens, suggests the company will… More
Their devices haven't been selling, their financials are awful, the stock price has been plummeting and they're headed toward bankruptcy.
Read the most recent pitches from players about DXCM.
Recs
CrotalusJoe
(< 20)
Submitted: 2/13/2019 9:28:48 PM :
Start Price:
$148.30
NASDAQ:DXCM Score:
+36.56
Increasing obesity/diabetes rates = need for their product
Recs
TMFProcess
(79.75)
Submitted: 1/12/2019 3:59:15 PM :
Start Price:
$140.43
NASDAQ:DXCM Score:
+37.47
Top dog in CGM space with multiple partnerships with pump providers with innovative technology. Most accurate CGM available with a focus on ease of use through smartphone integration. G6 no-calibration product is still growing and its Verily product in partnership with Alphabet is coming to market soon(?) In a growing diabetes market, Dexcom is positioned to outperform
Recs
TMFEBCapital
(86.35)
Submitted: 6/14/2018 9:17:40 AM :
Start Price:
$99.37
NASDAQ:DXCM Score:
+113.34
Its platform agnostic blood glucose monitor is a component in both Insulet and Tandem Diabetes closed-loop (artificial pancreas) solution and efforts to pair up DexCom's CGMs with other insulin systems, including smart pens, suggests the company will remain at the forefront of this technology. As diabetes becomes more common and patients increasingly leverage technology to manage their disease, I suspect DexCom will reward investors with additional gains.
Find the members with the highest scoring picks in DXCM.
ardys13 (< 20) Score: +5,707.62
The Score Leader is the player with the highest score across all their picks in DXCM.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| ardys13 | < 20 | 2/9/2009 |
|
1Y | $3.70 | +5,974.59% | +266.97% | +5,707.62 | 1 Comment | |
| bigrick22 | 89.49 | 3/24/2008 |
|
NS | $4.00 | +5,519.00% | +144.92% | +5,374.08 | 0 Comment | |
| CleverKat | 59.26 | 3/24/2008 |
|
NS | $4.27 | +5,163.70% | +142.25% | +5,021.45 | 0 Comment | |
| MEGIN7790 | < 20 | 4/4/2008 |
|
NS | $4.45 | +4,950.79% | +137.60% | +4,813.18 | 0 Comment | |
| cpalerm | 93.08 |
|
|
5Y | $4.32 | +5,102.78% | +304.04% | +4,798.74 | 1 Comment | |
| LazyTimeMoney | 69.50 | 4/7/2008 |
|
NS | $5.04 | +4,359.52% | +137.20% | +4,222.32 | 0 Comment | |
| jabrink | 77.84 | 4/7/2008 |
|
3W | $5.07 | +4,333.14% | +137.01% | +4,196.12 | 0 Comment | |
| GriffinRex | 84.92 | 4/8/2008 |
|
3M | $5.17 | +4,247.39% | +139.67% | +4,107.72 | 0 Comment | |
| cash4metoo | 58.61 | 5/28/2009 |
|
1Y | $5.34 | +4,108.99% | +251.69% | +3,857.30 | 0 Comment | |
| YahooSIRIous | 81.12 | 7/13/2009 |
|
5Y | $5.35 | +4,101.12% | +258.24% | +3,842.88 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
